The Monitoring Medicines Project: A Multinational Pharmacovigilance and Public Health Project

Drug Safety

Volumn 38, Issue 4, 2015, Pages 319-328

  Pal, Shanthi N ^a   Olsson, Sten ^b   Brown, Elliot G ^c  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UPPSALA MONITORING CENTRE   (Sweden)

^c Elliot Brown (Consulting) Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUROPEAN UNION; HUMAN; INTERNATIONAL COOPERATION; MEDICATION ERROR; POSTMARKETING SURVEILLANCE; PROCEDURES; PUBLIC HEALTH; STATISTICS AND NUMERICAL DATA; WORLD HEALTH ORGANIZATION;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUROPEAN UNION; HUMANS; INTERNATIONALITY; MEDICATION ERRORS; PRODUCT SURVEILLANCE, POSTMARKETING; PUBLIC HEALTH; WORLD HEALTH ORGANIZATION;

EID: 84937760153     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0283-y     Document Type: Review

References (33)

1. Monitoring Medicines: monitoring medicines for the purpose of patient safety [Poster]. World Research and Innovation Congress, Brussels, 5–6 June, 2013.
2. Van Hunsel F, Härmark L, Pal S, Olsson S, van Groothest K. Experiences with adverse drug reaction reporting from the general public: an 11-country survey. Drug Saf. 2012;35(1):45–60.
3. Plöen M, Wallberg M, Olsson S. User-driven development of a web-based tool for patient reporting of drug-related harm. Drug Safety. doi:10.1007/s40264-015-0276-x.
4. Benabdallah G, Benkirane R, Khattabi A, Edwards IR, Bencheikh RS The involvement of pharmacovigilance centres in medication errors detection. A questionnaire-based analysis. Int J Risk Saf Med. 2011;23:17–29.
5. Benkirane R, Soulaymani-Bencheikh R, Khattabi A et al. Assessment of a new instrument for detecting preventable adverse drug reactions. Drug Safety. doi:10.1007/s40264-014-0257-5.
6. World Health Organisation. Reporting and learning systems for medication errors: the role of pharmacovigilance centres. Geneva: WHO Press; 2014.
7. Juhlin K, Karimi G, Andér M, et al. Using VigiBase to identify substandard medicines: detection capacity and key prerequisites. Drug Safety. doi:10.1007/s40264-015-0271-2.
8. Layton D, Shakir S. Prescription-event monitoring (PEM): the evolution to the new Modified PEM and its support of risk management. In: Andrews EB, Moore N, editors. Mann’s pharmacovigilance. 3rd ed. Chichester: Wiley Blackwell; 2014. p. 359–84.
9. Harrison-Woolrych M. Prescription-event monitoring in New Zealand. In: Andrews EB, Moore N, editors. Mann’s pharmacovigilance. 3rd ed. Chichester: Wiley Blackwell; 2014. p. 385–402.
10. Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf. 2013;36:75–81.
11. Setkina S, Dotsenko M, Bondar S et al. Safety and effectiveness of HAART in treatment-naïve HIV patients: preliminary findings of a Cohort Event Monitoring Study in Belarus. Drug Saf. doi:10.1007/s40264-015-0279-7.
12. Ndagije H, Nambasa V, Namagala E et al. Targeted Spontaneous Reporting of suspected renal toxicity in patients undergoing Highly Active Anti-Retroviral Therapy in two public health facilities in Uganda. Drug Saf. doi:10.1007/s40264-015-0277-9.
13. Nyambayo P, Gavi S, Mahlangu G et al. Pilot phase of targeted spontaneous reporting of adverse drug reactions due to antiretrovirals and anti-tuberculosis medicines: Zimbabwe experience. Oral communication. First African congress of pharmacovigilance. Actes du Congrès, Rabat; 2013. pp. 42–44. http://www.smpv.ma. Accessed 7 Nov 2014.
14. World Health Organisation. Safety monitoring of medicinal products: reporting system for the general public. Geneva: WHO Press; 2012.
15. Caster O, Edwards IR, Norén GN, Lindquist M. Earlier discovery of pregabalin’s dependence potential might have been possible. Eur J Clin Pharmacol. 2011;67(3):319–20.
16. World Health Organisation. A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis: enhancing the safety of the TB patient. Geneva: WHO Press; 2012.
17. PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium). http://www.imi-protect.eu. Accessed 12 June 2014.
18. ENCEPP (European Network of Centres for Pharmacoepidemiology and Pharmacovigilance). http://www.encepp.eu. Accessed 12 June 2014.
19. EU-ADR. http://euadr-project.org. Accessed 12 June 2014.
20. SALUS (Scalable, Standard based Interoperability Framework for Sustainable Proactive Post Market Safety Studies). http://www.salusproject.eu. Accessed 17 Aug 2014.
21. OMOP (Observational Medical Outcomes Partnership). http://omop.org. Accessed 12 June 2014.
22. FDA Sentinel Initiative. http://www.fda.gov/Safety/FDAsSentinelInitiative/ default.htm. Accessed 12 June 2014.
23. Mini-Sentinel http://mini-sentinel.org. Accessed 12 June 2014.
24. European Commission: assessment of the community system of pharmacovigilance—European Commission Public Consultation—presentation of results. European Commission Enterprise and Industry Directorate-General. 2007. http://ec.europa.eu/health/files/pharmacovigilance/docs/2007_02_26/analysis_consultation_responses_en.pdf. Accessed 7 Nov 2014.
25. World Health Organisation. The importance of pharmacovigilance: safety monitoring of medicinal products, WHO, Geneva. 2002 http://apps.who.int/medicinedocs/en/d/Js4893e/. Accessed 29 Oct 2014.
26. Margraff F, Bertram D. Adverse drug reaction reporting by patients: an overview of fifty countries. Drug Saf. 2014. doi:10.1007/s40264-014-0162-y.
27. Härmark L, van Hunsel F, Grundmark B. ADR reporting by general public: lessons learned from the Dutch and Swedish systems. Drug Saf. doi:10.1007/s40264-015-0264-1.
28. Kenneth Hartigan-Go. Empowering consumers as contributors for health product safety: lessons from the Philippines. Drug Saf. doi:10.1007/s40264-015-0274-z.
29. WHO Expert Committee on Drug Dependence. World Health Organisation technical report series 942, 34th report. Geneva: WHO Press; 2006.
30. Institute of Medicine. Countering the problem of falsified and substandard drugs. Washington, DC: The National Academies Press; 2013.
31. Cousins D, Gerrett D, Richards N, Jadeja MM. Initiatives to identify and mitigate medication errors in England. Drug Saf. doi:10.1007/s40264-015-0270-3.
32. Abwao E, Sumbi V, Kusu N, Njeri M. Kenya sets record as a leader in ADR reports. Pharmacy and Poisons board newsletter. 2014;2:9–10. http://pharmacyboardkenya.org. Accessed 7 Nov 2014.
33. World Health Organisation. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. Geneva: WHO Press. 2013. http://www.who.int/tb/challenges/mdr/bedaquiline/en/. Accessed 30 Oct 2014.